NO962568L - Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom - Google Patents

Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom

Info

Publication number
NO962568L
NO962568L NO962568A NO962568A NO962568L NO 962568 L NO962568 L NO 962568L NO 962568 A NO962568 A NO 962568A NO 962568 A NO962568 A NO 962568A NO 962568 L NO962568 L NO 962568L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
treatment
pla2 inhibitors
phospholase
Prior art date
Application number
NO962568A
Other languages
English (en)
Other versions
NO962568D0 (no
Inventor
James Allen Clemens
Michael Joseph Sofia
Diane Teresa Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO962568D0 publication Critical patent/NO962568D0/no
Publication of NO962568L publication Critical patent/NO962568L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det er beskrevet fremgangsmåter for behandling eller forebyggelse av Alzhelmer's sykdom i et pattedyr som Innbefatter administrering til et pattedyr som har behov for dette av en effektiv mengde av en Inhibitor av fosfollpaee A£. Det er også tllvelebragt serier av forbindelser som er nyttige som Inhibitorer av fosfollpase k^, spesielt cytosollsk fosfollpase A2.
NO962568A 1993-12-23 1996-06-17 Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom NO962568L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,544 US5478857A (en) 1993-12-23 1993-12-23 Use of PLA2 inhibitors as treatment for alzheimer's disease
PCT/US1994/014504 WO1995017183A1 (en) 1993-12-23 1994-12-14 Use of pla2 inhibitors as treatment for alzheimer's disease

Publications (2)

Publication Number Publication Date
NO962568D0 NO962568D0 (no) 1996-06-17
NO962568L true NO962568L (no) 1996-08-09

Family

ID=22632512

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962568A NO962568L (no) 1993-12-23 1996-06-17 Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom

Country Status (13)

Country Link
US (2) US5478857A (no)
EP (1) EP0735870A4 (no)
JP (1) JPH09507069A (no)
CN (1) CN1142768A (no)
AU (1) AU688446B2 (no)
BR (1) BR9408407A (no)
CA (1) CA2179649A1 (no)
CZ (1) CZ178096A3 (no)
FI (1) FI962557A (no)
HU (1) HUT75335A (no)
NO (1) NO962568L (no)
WO (1) WO1995017183A1 (no)
ZA (1) ZA9410041B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996036347A1 (en) * 1995-05-17 1996-11-21 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
JPH11506923A (ja) * 1995-06-06 1999-06-22 アセナ ニューロサイエンシーズ，インコーポレイテッド 新しいカテプシンならびにその阻害のための方法および組成物
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
US5707821A (en) * 1995-06-07 1998-01-13 Athena Neurosciences, Inc. Identification of phospholipase A2 inhibitors in Aβ peptide-mediated neurodegenerative disease
US5866318A (en) * 1995-06-07 1999-02-02 Athena Neurosciences, Inc. Inhibition of phospholipase A2 to reduce neuronal cell death
AU718462B2 (en) * 1995-08-08 2000-04-13 University Of Alabama At Birmingham Research Foundation, The Regulation of alzheimer's disease related proteins and uses thereof
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5663059A (en) * 1996-05-10 1997-09-02 Incyte Pharmaceuticals, Inc. Human phospholipase inhibitor
PL334516A1 (en) * 1996-11-22 2000-02-28 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl)amino cid amides, pharmaceutic agent containing them and method of inhibiting eduction and/or synthesis of beta-amyloid peptide using such compounds
US6153652A (en) * 1996-11-22 2000-11-28 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US5965614A (en) 1996-11-22 1999-10-12 Athena Neurosciences, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP0944580A2 (en) * 1996-11-22 1999-09-29 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and methods for inhibiting beta-amyloid peptide release and/or its synthesis
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
WO1998025600A1 (en) * 1996-12-13 1998-06-18 Eli Lilly And Company Leukotriene antagonists for treatment or inhibition of gout
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
WO1998042650A2 (en) * 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cystic fibrosis
US6350892B1 (en) * 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
WO1999015129A2 (en) 1997-09-23 1999-04-01 Bristol-Myers Squibb Company SELECTIVE cPLA2 INHIBITORS
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6774125B2 (en) * 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
AUPP609198A0 (en) * 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US20030149000A1 (en) * 1998-11-10 2003-08-07 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds
US6924391B2 (en) 2000-05-11 2005-08-02 Bristol-Myers Squibb Company Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors
CA2407088A1 (en) * 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Beta-secretase inhibitors
AU2001267825A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
WO2002000255A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre le cancer
AU9287401A (en) 2000-09-27 2002-04-08 Merck & Co Inc Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU2002248221B2 (en) * 2000-10-31 2006-08-17 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU2001218841A1 (en) * 2000-11-07 2002-05-21 I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
US6867320B2 (en) * 2002-02-21 2005-03-15 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivatives and use thereof
US20030225011A1 (en) * 2002-05-31 2003-12-04 Samuel David Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease
WO2003101487A1 (en) * 2002-05-31 2003-12-11 Mcgill University Use of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease
AU2003237397A1 (en) * 2002-06-04 2003-12-19 Sequenom, Inc. Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
US20050239077A1 (en) * 2002-06-27 2005-10-27 Adam Gail I R Diagnosing predisposition to fat deposition and associated conditions
WO2004002296A2 (en) * 2002-06-27 2004-01-08 Sequenom, Inc. Therapeutic methods for reducing fat deposition and treating associated conditions
US20040049134A1 (en) * 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
US20050192265A1 (en) * 2003-03-20 2005-09-01 Thompson Richard C. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
CA2535665A1 (en) 2003-08-14 2005-02-24 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivative and use thereof
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
CA3145446A1 (en) * 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada Cpla2e inducing agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814339A (en) * 1986-02-11 1989-03-21 Advanced Biologics, Inc. Treatment for Alzheimer's disease
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
US4788304A (en) * 1987-12-07 1988-11-29 American Home Products Corporation Phospholipase A2 inhibitors
US5070207A (en) * 1990-04-26 1991-12-03 American Home Products Corporation Phospholipase A2 inhibitors
US5171864A (en) * 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5290817A (en) * 1992-06-09 1994-03-01 The Du Pont Merck Pharmaceutical Co. Substituted 1-benzylindanes and their use as inhibitors of phospholipase A2
US5380740A (en) * 1993-04-28 1995-01-10 G. D. Searle & Co. Anti-inflammatory compounds, compositions and method of use thereof

Also Published As

Publication number Publication date
WO1995017183A1 (en) 1995-06-29
CZ178096A3 (cs) 1998-03-18
CA2179649A1 (en) 1995-06-29
US5478857A (en) 1995-12-26
FI962557A0 (fi) 1996-06-19
EP0735870A4 (en) 1998-08-19
HU9601741D0 (en) 1996-08-28
EP0735870A1 (en) 1996-10-09
ZA9410041B (en) 1996-06-18
CN1142768A (zh) 1997-02-12
AU688446B2 (en) 1998-03-12
US5563164A (en) 1996-10-08
HUT75335A (en) 1997-05-28
AU1402895A (en) 1995-07-10
BR9408407A (pt) 1997-08-05
JPH09507069A (ja) 1997-07-15
FI962557A (fi) 1996-08-22
NO962568D0 (no) 1996-06-17

Similar Documents

Publication Publication Date Title
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
NO983019L (no) Fremgangsmåte for inhibering av fotoaldring av hud
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE69629578D1 (de) Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut
BR9811099A (pt) Inibidores de urocinase
NO961326L (no) Inhibitorer av -amyloidproteinproduksjon
BR0017075A (pt) Derivados de piridopirimidinona para tratamento de doença neurodegenerativa
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
HUP0402506A2 (hu) FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
ATE357918T1 (de) Verwendung von 2-(4-ethoxy-phenyl)-3-(4- methanesulfonyl-phenyl)-pyrazolo(1,5-b)pyridazi e zur behandlung von nichtulzerativer dyspepsie
BR9712792A (pt) Inibidores de metaloprotease bidentada.
DE69512589T2 (de) Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application